Your browser doesn't support javascript.
loading
Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere, Lieven; Thomas, Melissa; Moons, Johnny; Coosemans, Willy; Lerut, Toni; Prenen, Hans; Haustermans, Karin; Van Veer, Hans; Nafteux, Philippe.
Afiliação
  • Depypere L; Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. lieven.depypere@uzleuven.be.
  • Thomas M; Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium. lieven.depypere@uzleuven.be.
  • Moons J; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Coosemans W; Department of Oncology, KU Leuven, Leuven, Belgium.
  • Lerut T; Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
  • Prenen H; Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
  • Haustermans K; Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
  • Van Veer H; Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.
  • Nafteux P; Department of Thoracic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
World J Surg Oncol ; 17(1): 89, 2019 May 27.
Article em En | MEDLINE | ID: mdl-31133018
ABSTRACT

BACKGROUND:

Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection.

METHODS:

We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002-2010 versus 2011-2015) and histology (adenocarcinoma versus squamous cell carcinoma).

RESULTS:

In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients' own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients' refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months.

CONCLUSIONS:

One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Adenocarcinoma / Esofagectomia / Terapia Neoadjuvante / Quimiorradioterapia Adjuvante / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Adenocarcinoma / Esofagectomia / Terapia Neoadjuvante / Quimiorradioterapia Adjuvante / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article